Episode 500: RAS Inhibition in Pancreatic Cancer (yes this is the Uromigos podcast..)

from The Uromigos · host The Uromigos

Filippo Pietrantonio from the National Cancer Institute of Milan joins the podcast to discuss the latest developments in RAS targeting in GI cancers, focusing on the exciting data with daraxonrasib in pancreatic cancer ahead of the ASCO 2026 plenary phase 3 data. We discuss the RAS pathway, prior unsuccessful targeting efforts and nuances on response and resistance.

Episode metadata supplied by the publisher feed · Published May 11, 2026

Embed this episode

Attribution link and audio player

Ready to play

Episode 500: RAS Inhibition in Pancreatic Cancer (yes this is the Uromigos podcast..)

0:00 35:16

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The Uromigos?

This episode is 35 minutes long.

When was this The Uromigos episode published?

This episode was published on May 11, 2026.

Can I download this The Uromigos episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!